Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 4 Thymus Neoplasms 1 Rhabdomyosarcoma 1 Pheochromocytoma 1 Paraganglioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Meningioma 1 Lymphoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 6 lutetium Lu 177 dotatate 4 Specimen Handling 4 Proton Therapy 3 Bevacizumab 3 gallium Ga 68 dotatate 2 abemaciclib 2 Protons 2 Observation 2 Ga(III)-DOTATOC 2 Everolimus 2 Elasticity Imaging Techniques 2 trametinib 1 regorafenib 1 pembrolizumab 1 olaparib 1 neratinib 1 fludarabine 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 capivasertib 1 cabozantinib 1 brigatinib 1 auricularum 1 apatinib 1 X-Rays 1 Watchful Waiting 1 Thrombectomy 1 Tablets 1 Surveys and Questionnaires 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Meningioma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all

NCT04997317 2025-04-13

PROMENADE

University Hospital, Basel, Switzerland

Phase 1/2 Recruiting

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡